{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:42:11Z","timestamp":1762605731160,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002905","name":"Gobierno de Colombia Ministerio de Salud y Proteccion Social","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vhri.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T02:01:27Z","timestamp":1714010487000},"page":"100983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Pharmacological Treatment for Adult Kidney Transplant Recipients in Colombia"],"prefix":"10.1016","volume":"42","author":[{"given":"Daysi","family":"Sanmartin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo","family":"Tamayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Esteban","family":"Orozco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang\u00e9lica","family":"Ord\u00f3\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Huertas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"\u00c1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Echeverry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Caicedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2014","series-title":"The number of kidney patients among those over 60 years of age with diabetes and\u00a0hypertension is increasing. Pan American Health Organization, PAHO. Published online","key":"10.1016\/j.vhri.2024.02.001_bib1"},{"author":"Lorenzo","key":"10.1016\/j.vhri.2024.02.001_bib3"},{"issue":"5","key":"10.1016\/j.vhri.2024.02.001_bib4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1681\/ASN.2008070730","article-title":"Combining GFR and albuminuria to classify CKD improves prediction of ESRD","volume":"20","author":"Hallan","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.vhri.2024.02.001_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1053\/j.ajkd.2007.06.013","article-title":"Testing for chronic kidney disease: a position statement from the national kidney foundation","volume":"50","author":"Vassalotti","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.vhri.2024.02.001_bib6","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.vhri.2024.02.001_bib7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2013.243","article-title":"Comments on KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney diseaseas","volume":"84","author":"Andrassy","year":"2013","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.vhri.2024.02.001_bib8","first-page":"1","article-title":"Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"10.1016\/j.vhri.2024.02.001_bib9","first-page":"227","article-title":"Uso de medicamentos inmunosupresores en pacientes con trasplante renal, hep\u00e1tico y de m\u00e9dula \u00f3sea, en una cl\u00ednica de nivel iii de bogot\u00e1","volume":"57","author":"L\u00f3pez","year":"2009","journal-title":"Rev Fac Med"},{"issue":"62","key":"10.1016\/j.vhri.2024.02.001_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20620","article-title":"Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model","volume":"20","author":"Jones-Hughes","year":"2016","journal-title":"Health Technol Assess (Rockv)"},{"year":"2019","series-title":"Consejo general de colegios oficiales de farmac\u00e9uticos. Solid Organ Transplant - Pharmacological Point No 132","key":"10.1016\/j.vhri.2024.02.001_bib12"},{"author":"Chandraker","key":"10.1016\/j.vhri.2024.02.001_bib13"},{"issue":"4","key":"10.1016\/j.vhri.2024.02.001_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/0272989X8600600403","article-title":"A\u00a0cost-effectiveness analysis of cyclosporine in cadaveric kidney transplantation","volume":"6","author":"Simon","year":"1986","journal-title":"Med Decis Making"},{"issue":"2","key":"10.1016\/j.vhri.2024.02.001_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.vhri.2012.09.013","article-title":"Cost utility of sirolimus versus tacrolimus for the primary prevention of graft rejection in renal transplant recipients in Mexico","volume":"1","author":"Rely","year":"2012","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2024.02.001_bib16","first-page":"1537","article-title":"Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales","volume":"8","author":"Muduma","year":"2014","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"10.1016\/j.vhri.2024.02.001_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10198-014-0579-3","article-title":"Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany","volume":"16","author":"J\u00fcrgensen","year":"2015","journal-title":"Eur J Health Econ"},{"issue":"7","key":"10.1016\/j.vhri.2024.02.001_bib18","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfx074","article-title":"Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation","volume":"32","author":"Snowsill","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.vhri.2024.02.001_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.vhri.2017.08.009","article-title":"Cost-effectiveness analysis of everolimus versus mycophenolate in kidney transplant recipients receiving no pharmacological prophylaxis for cytomegalovirus infection: a short-term pharmacoeconomic evaluation (12 months)","volume":"14","author":"Felipe","year":"2017","journal-title":"Value Heal Reg Issues"},{"issue":"10","key":"10.1016\/j.vhri.2024.02.001_bib20","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.clinthera.2018.08.017","article-title":"A cost-effectiveness analysis of rabbit antithymocyte globulin versus antithymocyte globulin-fresenius as induction therapy for patients with kidney transplantation from donation after cardiac death in China","volume":"40","author":"Xuan","year":"2018","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.vhri.2024.02.001_bib21","doi-asserted-by":"crossref","first-page":"e1720","DOI":"10.1097\/MJT.0000000000000186","article-title":"Sirolimus versus tacrolimus as primary immunosuppressant after renal transplantation: a meta-analysis and economics evaluation","volume":"23","author":"Liu","year":"2016","journal-title":"Am J Ther"},{"issue":"4","key":"10.1016\/j.vhri.2024.02.001_bib22","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S0041-1345(03)00378-6","article-title":"Cost-effectiveness analysis of basixilimab induction and calcineurin-sparing protocols in \u201cold to old\u201d programs using Markov models","volume":"35","author":"Emparan","year":"2003","journal-title":"Transplant Proc"},{"issue":"17","key":"10.1016\/j.vhri.2024.02.001_bib23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2165\/00019053-200321170-00003","article-title":"The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes","volume":"21","author":"Orme","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vhri.2024.02.001_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00019053-200624010-00006","article-title":"Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK","volume":"24","author":"McEwan","year":"2006","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.vhri.2024.02.001_bib25","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1399-0012.2006.00518.x","article-title":"Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia","volume":"20","author":"Gordois","year":"2006","journal-title":"Clin Transpl"},{"issue":"9","key":"10.1016\/j.vhri.2024.02.001_bib26","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1681\/ASN.2007040495","article-title":"Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation","volume":"19","author":"Earnshaw","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.vhri.2024.02.001_bib27","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ndt\/gfp174","article-title":"The cost-effectiveness of induction immunosuppression in kidney transplantation","volume":"24","author":"Morton","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.vhri.2024.02.001_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10198-009-0148-3","article-title":"Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach","volume":"11","author":"J\u00fcrgensen","year":"2010","journal-title":"Eur J Health Econ"},{"issue":"9","key":"10.1016\/j.vhri.2024.02.001_bib29","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1016\/j.transproceed.2011.09.092","article-title":"Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation","volume":"43","author":"Gamboa","year":"2011","journal-title":"Transplant Proc"},{"year":"2017","series-title":"The IQWiG checklist for indirect comparison and network meta-analyses. The Evid Forum Inst Qual Effic Healthc (IQWiG)","author":"Schmetz","key":"10.1016\/j.vhri.2024.02.001_bib30"},{"key":"10.1016\/j.vhri.2024.02.001_bib31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.zefq.2019.11.003","article-title":"GRADE guidelines:18. How Robins-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence","volume":"150","author":"Morche","year":"2020","journal-title":"Z\u00a0Evid Fortbild Qual Gesundhwes"},{"issue":"3","key":"10.1016\/j.vhri.2024.02.001_bib32","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s10157-017-1480-z","article-title":"Induction therapy of basiliximab versus antithymocyte globulin in renal allograft: a systematic review and meta-analysis","volume":"22","author":"Wang","year":"2018","journal-title":"Clin Exp Nephrol"},{"issue":"10","key":"10.1016\/j.vhri.2024.02.001_bib33","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1097\/TP.0000000000002769","article-title":"Mammalian target of rapamycin inhibitors combined with calcineurin inhibitors as initial immunosuppression in renal transplantation: a meta-analysis","volume":"103","author":"Montero","year":"2019","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.vhri.2024.02.001_bib34","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40273-020-00937-z","article-title":"Estimating transition probabilities from published evidence: a tutorial for decision modelers","volume":"38","author":"Gidwani","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.vhri.2024.02.001_bib35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/heapol\/czab146","article-title":"Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia","volume":"37","author":"Espinosa","year":"2022","journal-title":"Health Policy Plan"},{"year":"2022","series-title":"Departamento Administrativo Nacional de Estad\u00edstica(DANE). Gross domestic product (GDP). Annual National Accounts","key":"10.1016\/j.vhri.2024.02.001_bib36"},{"issue":"9","key":"10.1016\/j.vhri.2024.02.001_bib37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00019053-200826090-00008","article-title":"Exploring uncertainty in cost-effectiveness analysis","volume":"26","author":"Claxton","year":"2008","journal-title":"Pharmacoeconomics"},{"year":"2012","series-title":"Economic evaluation of medicines and health technologies: principles, methods and applications in health policy. Springer Healthcare Madrid","author":"Soto","key":"10.1016\/j.vhri.2024.02.001_bib38"},{"year":"2016","series-title":"Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for Preparing a Submission to the Pharmaceutical Benefits Advisory Committee. version 5.0. Commonwealth of Australia: Department of Health","key":"10.1016\/j.vhri.2024.02.001_bib39"},{"year":"2015","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","key":"10.1016\/j.vhri.2024.02.001_bib40"},{"issue":"4","key":"10.1016\/j.vhri.2024.02.001_bib41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force Report","volume":"12","author":"Drummond","year":"2009","journal-title":"Value Health"},{"year":"2006","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","key":"10.1016\/j.vhri.2024.02.001_bib42"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992400013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992400013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:33:45Z","timestamp":1762605225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221210992400013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":40,"alternative-id":["S221210992400013X"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.02.001","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Pharmacological Treatment for Adult Kidney Transplant Recipients in Colombia","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100983"}}